* Apyx Medical Corp APYX.OQ APYX.O is expected to show a
fall
in quarterly revenue when it reports results on May 11.
* The Clearwater Florida-based company is expected to
report a
13.0% decrease in revenue to $10.867 million from $12.49 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. The company's guidance on March 16
2023, for the period ended March 31, was for revenue between
$10.80 million and $11.20 million.
* Refinitiv's mean analyst estimate for Apyx Medical Corp
is for
a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Apyx
Medical Corp
is $7.5, above its last closing price of $3.48.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 -0.15 -0.14 -0.17 Missed -19.3
Sep. 30 2022 -0.15 -0.14 -0.17 Missed -17.2
Jun. 30 2022 -0.19 -0.19 -0.16 Beat 14.7
Mar. 31 2022 -0.14 -0.15 -0.17 Missed -15.9
Dec. -0.10 -0.11 -0.06 Beat 45.5
31 2021
Sep. 30 2021 -0.15 -0.15 -0.12 Beat 20
Jun. 30 2021 -0.16 -0.15 -0.12 Beat 18.5
Mar. 31 2021 -0.14 -0.14 -0.14 Met 1.8
This summary was machine generated May 9 at 15:04 GMT. All
figures in US dollars unless otherwise stated